Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Details
Serval ID
serval:BIB_C026E9F13CC7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Journal
Journal of hypertension
Working group(s)
Missed Dose Study Group
Contributor(s)
Redon J., Pascual J.M., Olivan-Martinez J., Martell N., Calvo-Gomez C., Lembo G., Benedetto F.A., De Curtis G., Desideri G., Dognini G.P., Ferri C., Fogari R., Ganau A., Gargiulo A., Gaudio G., Germanò G., Malatino L., Bucci M., Mos L., Novo S., Pedrinelli R., Perticone F., Portaluppi F., Mulé G., Sarzani R., Schillaci G., Spagnuolo V., Strazzullo P., Taddei S., Trimarco B., Veglio F., Verdecchia P., Volpe M., Tsioufis C., Zakopoulos N., Zamboulis C., Schmieder R.E., Bönner G., Sehnert W., Haller H., Scholze J., Burnier M., Hayoz D., Asmar R., Blacher J., Benetos A., Gosse P., Mounier-Vehier C., Thuillez C.
ISSN
1473-5598 (Electronic)
ISSN-L
0263-6352
Publication state
Published
Issued date
02/2016
Volume
34
Number
2
Pages
359-367
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Randomized Controlled Trial
Publication Status: ppublish
Publication Status: ppublish
Abstract
Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped.
The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed.
In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg or perindopril 4-8 mg/amlodipine 5-10 mg for 24 weeks. The main outcome was the sitting office DBP after 24 weeks of treatment at 48 h from last administration.
The olmesartan/amlodipine combination reached noninferiority criteria in reduction of office DBP after 24 weeks of treatment and after the missed dose, compared with the perindopril/amlodipine combination (-11.7 and -10.5 mmHg, respectively). Office SBP and pulse pressure were significantly lower in both groups after 24 weeks of treatment and 48 h after the missed dose, observing a trend to greater SBP reduction in the olmesartan/amlodipine group.
The combination olmesartan/amlodipine is safe, well tolerated, and as effective as the combination of perindopril/amlodipine in the control of essential hypertension in patients with diabetes mellitus. A missed dose does not leave the patients unprotected in both treatments; however, a faster control with less dose increment is observed with olmesartan/amlodipine.
The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed.
In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg or perindopril 4-8 mg/amlodipine 5-10 mg for 24 weeks. The main outcome was the sitting office DBP after 24 weeks of treatment at 48 h from last administration.
The olmesartan/amlodipine combination reached noninferiority criteria in reduction of office DBP after 24 weeks of treatment and after the missed dose, compared with the perindopril/amlodipine combination (-11.7 and -10.5 mmHg, respectively). Office SBP and pulse pressure were significantly lower in both groups after 24 weeks of treatment and 48 h after the missed dose, observing a trend to greater SBP reduction in the olmesartan/amlodipine group.
The combination olmesartan/amlodipine is safe, well tolerated, and as effective as the combination of perindopril/amlodipine in the control of essential hypertension in patients with diabetes mellitus. A missed dose does not leave the patients unprotected in both treatments; however, a faster control with less dose increment is observed with olmesartan/amlodipine.
Keywords
Adult, Aged, Amlodipine/adverse effects, Amlodipine/therapeutic use, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Antihypertensive Agents/adverse effects, Antihypertensive Agents/therapeutic use, Blood Pressure/drug effects, Calcium Channel Blockers/therapeutic use, Diabetes Mellitus, Type 2/complications, Double-Blind Method, Drug Combinations, Female, Humans, Hypertension/complications, Hypertension/drug therapy, Imidazoles/adverse effects, Imidazoles/therapeutic use, Male, Medication Adherence, Middle Aged, Perindopril/adverse effects, Perindopril/therapeutic use, Tetrazoles/adverse effects, Tetrazoles/therapeutic use, Treatment Outcome
Pubmed
Create date
15/02/2017 17:17
Last modification date
20/08/2019 16:34
Usage data
